• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of frequency of silent cerebral infarction as assessed by serum neuron specific enolase in patients with non-valvular atrial fibrillation: < em > Warfarin versus direct oral anticoagulant < /em >
CONCLUSIONS: Our study revealed that DOACs were associated with significantly reduced SCIs compared with warfarin, probably due to more effective and consistent therapeutic level of anticoagulation.PMID:35469540 | DOI:10.1080/00015385.2022.2066777
Source: Acta Cardiologica - April 26, 2022 Category: Cardiology Authors: Huseyin Goksuluk Nil Ozyuncu Irfan Veysel Duzen Veysel Kutay Vurgun Turkan Seda Tan Sadi Gulec Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: a Systematic Review and Meta-analysis
ConclusionDOACs were associated with better efficacy and safety profiles than warfarin in atrial fibrillation patients with prior stroke, more specifically a lower risk of systemic embolism, all-cause mortality, and ICH.
Source: Cardiovascular Drugs and Therapy - April 25, 2022 Category: Cardiology Source Type: research

Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
AbstractPurpose of ReviewDirect oral anticoagulants (DOACs) are increasingly used for the treatment and prevention of thromboembolic events in patients with non-valvular atrial fibrillation (AF). Evidence regarding their role in patients with AF and concurrent valvular heart disease (VHD) continues to evolve.Recent FindingsPost hoc analyses of randomized clinical trials suggest that DOACs are non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with AF and VHD. Emerging evidence from observational data showed a favorable benefit-risk profile for DOACs compared to warfarin in patients with ...
Source: Current Cardiology Reports - April 23, 2022 Category: Cardiology Source Type: research

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
CONCLUSIONS: Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.PMID:35449605 | PMC:PMC9017587 | DOI:10.1155/2022/4713826
Source: Cardiology Research and Practice - April 22, 2022 Category: Cardiology Authors: Ze Li Xiaozhen Wang Dandan Li Aiping Wen Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20